PMC:7212965 / 40480-40816 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T88","span":{"begin":41,"end":48},"obj":"Body_part"},{"id":"T89","span":{"begin":249,"end":252},"obj":"Body_part"}],"attributes":[{"id":"A88","pred":"fma_id","subj":"T88","obj":"http://purl.org/sig/ont/fma/fma7148"},{"id":"A89","pred":"fma_id","subj":"T89","obj":"http://purl.org/sig/ont/fma/fma278683"}],"text":"discomfort, 4.2% (4 of 99) with reported stomach ache, and 4.2% (4 of 99) with diarrhea. Additionally, there were 2 serious adverse events of acute gastritis, which both led to drug discontinuation. When lopinavir/ritonavir is used in patients with HIV, diarrhea is the most common GI adverse events (10%–30%), with greater prevalence a"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T68","span":{"begin":41,"end":48},"obj":"Body_part"}],"attributes":[{"id":"A68","pred":"uberon_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/UBERON_0000945"}],"text":"discomfort, 4.2% (4 of 99) with reported stomach ache, and 4.2% (4 of 99) with diarrhea. Additionally, there were 2 serious adverse events of acute gastritis, which both led to drug discontinuation. When lopinavir/ritonavir is used in patients with HIV, diarrhea is the most common GI adverse events (10%–30%), with greater prevalence a"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T208","span":{"begin":79,"end":87},"obj":"Disease"},{"id":"T209","span":{"begin":148,"end":157},"obj":"Disease"},{"id":"T210","span":{"begin":254,"end":262},"obj":"Disease"}],"attributes":[{"id":"A208","pred":"mondo_id","subj":"T208","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"},{"id":"A209","pred":"mondo_id","subj":"T209","obj":"http://purl.obolibrary.org/obo/MONDO_0004966"},{"id":"A210","pred":"mondo_id","subj":"T210","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"}],"text":"discomfort, 4.2% (4 of 99) with reported stomach ache, and 4.2% (4 of 99) with diarrhea. Additionally, there were 2 serious adverse events of acute gastritis, which both led to drug discontinuation. When lopinavir/ritonavir is used in patients with HIV, diarrhea is the most common GI adverse events (10%–30%), with greater prevalence a"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T86","span":{"begin":177,"end":181},"obj":"Chemical"},{"id":"T87","span":{"begin":204,"end":223},"obj":"Chemical"},{"id":"T88","span":{"begin":204,"end":213},"obj":"Chemical"},{"id":"T89","span":{"begin":214,"end":223},"obj":"Chemical"},{"id":"T90","span":{"begin":282,"end":284},"obj":"Chemical"}],"attributes":[{"id":"A86","pred":"chebi_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A87","pred":"chebi_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A88","pred":"chebi_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A89","pred":"chebi_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A90","pred":"chebi_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/CHEBI_73907"}],"text":"discomfort, 4.2% (4 of 99) with reported stomach ache, and 4.2% (4 of 99) with diarrhea. Additionally, there were 2 serious adverse events of acute gastritis, which both led to drug discontinuation. When lopinavir/ritonavir is used in patients with HIV, diarrhea is the most common GI adverse events (10%–30%), with greater prevalence a"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T184","span":{"begin":79,"end":87},"obj":"Phenotype"},{"id":"T185","span":{"begin":148,"end":157},"obj":"Phenotype"},{"id":"T186","span":{"begin":254,"end":262},"obj":"Phenotype"}],"attributes":[{"id":"A184","pred":"hp_id","subj":"T184","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A185","pred":"hp_id","subj":"T185","obj":"http://purl.obolibrary.org/obo/HP_0005263"},{"id":"A186","pred":"hp_id","subj":"T186","obj":"http://purl.obolibrary.org/obo/HP_0002014"}],"text":"discomfort, 4.2% (4 of 99) with reported stomach ache, and 4.2% (4 of 99) with diarrhea. Additionally, there were 2 serious adverse events of acute gastritis, which both led to drug discontinuation. When lopinavir/ritonavir is used in patients with HIV, diarrhea is the most common GI adverse events (10%–30%), with greater prevalence a"}

{"project":"LitCovid-sentences","denotations":[{"id":"T254","span":{"begin":89,"end":198},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"discomfort, 4.2% (4 of 99) with reported stomach ache, and 4.2% (4 of 99) with diarrhea. Additionally, there were 2 serious adverse events of acute gastritis, which both led to drug discontinuation. When lopinavir/ritonavir is used in patients with HIV, diarrhea is the most common GI adverse events (10%–30%), with greater prevalence a"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1141","span":{"begin":282,"end":284},"obj":"Gene"},{"id":"1146","span":{"begin":235,"end":243},"obj":"Species"},{"id":"1151","span":{"begin":204,"end":223},"obj":"Chemical"},{"id":"1158","span":{"begin":41,"end":53},"obj":"Disease"},{"id":"1159","span":{"begin":79,"end":87},"obj":"Disease"},{"id":"1160","span":{"begin":142,"end":157},"obj":"Disease"},{"id":"1161","span":{"begin":249,"end":252},"obj":"Disease"},{"id":"1162","span":{"begin":254,"end":262},"obj":"Disease"}],"attributes":[{"id":"A1141","pred":"tao:has_database_id","subj":"1141","obj":"Gene:2770"},{"id":"A1146","pred":"tao:has_database_id","subj":"1146","obj":"Tax:9606"},{"id":"A1151","pred":"tao:has_database_id","subj":"1151","obj":"MESH:C558899"},{"id":"A1158","pred":"tao:has_database_id","subj":"1158","obj":"MESH:D063806"},{"id":"A1159","pred":"tao:has_database_id","subj":"1159","obj":"MESH:D003967"},{"id":"A1160","pred":"tao:has_database_id","subj":"1160","obj":"MESH:D005756"},{"id":"A1161","pred":"tao:has_database_id","subj":"1161","obj":"MESH:D015658"},{"id":"A1162","pred":"tao:has_database_id","subj":"1162","obj":"MESH:D003967"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"discomfort, 4.2% (4 of 99) with reported stomach ache, and 4.2% (4 of 99) with diarrhea. Additionally, there were 2 serious adverse events of acute gastritis, which both led to drug discontinuation. When lopinavir/ritonavir is used in patients with HIV, diarrhea is the most common GI adverse events (10%–30%), with greater prevalence a"}